jRCT2031260096招募中不适用
A Phase 1, Open-Label Study to Evaluate the Effect of Food on the Pharmacokinetics of Zipalertinib (TAS6417 FE study)
未提供0 个研究点目标入组 16 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Provided written informed consent.
- •Is >= 18 years of age at the time of informed consent.
- •Histologically or cytologically confirmed locally advanced or metastatic nonsqauamous NSCLC, characterized at or after the time of locally advanced or metastatic disease diagnosis by EGFR mutation.
- •Refractory to prior therapies, unable to receive generally accepted standard therapies, or unwilling to receive such therapies.
排除标准
- •Documented EGFR C797S mutation-positive status Histologically or cytologically confirmed locally advanced or metastatic nonsqauamous NSCLC
- •Have any unresolved toxicity of Grade >= 2 from previous anticancer treatment except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
- •Have allergy to any components of the high-fat test meal.
- •Use tobacco products.
研究者
相似试验
已完成
1 期
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose2022-500921-34-00Achieve Life Sciences Inc.56
招募中
1 期
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications2023-506227-29-00AbbVie Deutschland GmbH & Co. KG60
招募中
1 期
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 StudyNon-Small Cell Lung Cancer2024-512515-45-01Theras Inc.45
招募中
不适用
CaDance304B-cell malignanciesjRCT2031250598500
招募中
1 期
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)2024-512089-32-00ADC Therapeutics SA121